PharmaSil
ActiveActs, filings and financial milestones
Deadline for the 2026 accounts:
2026
25-06
abbreviated format · 36 days before the deadline
2025
31-12
Financial
Equity above €200,000equity €241,248 ▲123%
With a profit in every financial year since 2024, equity grows to €241,248.
27-06
abbreviated format · 34 days before the deadline
2024
02-04
Gazette deed
IncorporationStarting capital €10,000 · Appointment: Stockman Xavier Luc Nicolas Jan Maria (director) · Founder16 points ▸
Gazette deed
Incorporation
Starting capital €10,000 · Appointment: Stockman Xavier Luc Nicolas Jan Maria (director) · Founder16 points ▸
- Incorporation, “PharmaSil” (deed in Dutch)
- Founder, Stockman Xavier Luc Nicolas Jan Maria
- Founding capital, €10,000
- Bank account, “BE57645109707035, bijzondere rekening namens vennootschap in oprichting” (deed in Dutch)
- Other provision, 26-03-2024
- Other provision, “naamskeuze, door notaris op hoogte gebracht van naamskeuze en mogelijke gevolgen” (deed in Dutch)
- Share issue, “vergoeding voor de inbrengen”, 100 (deed in Dutch)
- Other provision, “Statutair onbeschikbare eigen vermogensrekening” (deed in Dutch)
- Other provision, “eenparig door comparanten, slot- en overgangsbepalingen” (deed in Dutch)
- Registered office clause, “2150 Borsbeek, Herentalsebaan 1” (deed in Dutch)
- Other provision, “website en e-mailadres” (deed in Dutch)
- Board rule, 1
- The act holds 4 more points.
Financial milestoneGazette deedNBB filingFinancial milestones sit on the financial year-end date, not the filing date.
Sources:Publications in the Belgian Official GazetteFilings with the National Bank
History
PharmaSil was incorporated on 28 March 2024 as a private limited company by one natural person, with a starting capital of €10,000.12 Stockman Xavier Luc Nicolas Jan Maria is director of the company, appointed in the act of 02-04-2024.2 The company has filed 2 sets of annual accounts, the latest for financial year 2025.3